Floatz Rating
C39/100
Confidence
Indicative
Sponsor
The Children's Hospital of Zhejiang University School of Medicine
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07586267CT.gov CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Systemic Lupus Erythematosus
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| qt-219cx (this asset) | The Children's Hospital of Zhejiang University School of Medicine | Early P1 | C · 39 |
| Dehydroepiandrosterone | National Center for Research Resources (NCRR) | P3 | BB |
| Warfarin | University College, London | P2 | B |
| Technetate(3-)-99Tc, (N-(4-(((2-Amino-1,4-Dihydro-4-Oxo-6-Pteridinyl)Methyl)Amino)Benzoyl)-D-.Gamma.-Glutamyl-(2S)-2-(Amino-.Kappa.N)-.Beta.-Alanyl-L-.Alpha.-Aspartyl-.Kappa.N-L-Cysteinato(6-)-.Kappa.N,.Kappa.S)Oxo-, Hydrogen (1:3), (Sp-5-24)- | Mayo Clinic | P2 | B |
| Rivaroxaban | University College, London | P2 | B |
| Cytarabine | National Center for Research Resources (NCRR) | P2 | B |
| Monovalent [B.1.351] Cov2 Pres Dtm-As03 | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Moderna Covid-19 Vaccine Rna | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Bcma-Cd19 Ccar T Cells | Peking University People's Hospital | P2 | CCC |
+26 more in the Systemic Lupus Erythematosus cohort
Other indications for qt-219cx
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Idiopathic Multidrug-Resistant Nephrotic Syndrome | — | Early P1 | C · 39 |
| IgA Glomerulonephritis | — | Early P1 | C · 39 |
| Systemic Sclerosis | — | Early P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- DehydroepiandrosteroneNational Center for Research Resources (NCRR)BB
- WarfarinUniversity College, LondonB
- Technetate(3-)-99Tc, (N-(4-(((2-Amino-1,4-Dihydro-4-Oxo-6-Pteridinyl)Methyl)Amino)Benzoyl)-D-.Gamma.-Glutamyl-(2S)-2-(Amino-.Kappa.N)-.Beta.-Alanyl-L-.Alpha.-Aspartyl-.Kappa.N-L-Cysteinato(6-)-.Kappa.N,.Kappa.S)Oxo-, Hydrogen (1:3), (Sp-5-24)-Mayo ClinicB
- RivaroxabanUniversity College, LondonB
- CytarabineNational Center for Research Resources (NCRR)B
Citation
Floatz Terminal. qt-219cx in Systemic Lupus Erythematosus. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/qt-219cx-systemic-lupus-erythematosus
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →